Investment
Features
FeesSafety
Academy
More
Pluang+

Barings BDC offers 12% yield at 21% discount with strong credit and portfolio gains.

Company Fundamentals
28 Sep 2026
Seeking Alpha
View Source
Bullish
Barings BDC offers 12% yield at 21% discount with strong credit and portfolio gains.

Barings BDC (BBDC) currently trades at a 21% discount to its book value and provides a total dividend yield of 12%. The company shows strong credit quality with some of the lowest non-accruals in the sector and improving portfolio performance. The recent termination of the Sierra CSA has freed up $67 million for redeployment, which, along with rising loan base rates and opportunities in software lending, supports positive income growth. Dividend coverage is solid at 106%, making BBDC fairly valued after a recent price increase but still supported by ongoing income drivers and robust credit metrics.

The story on Barings BDC (BBDC) is presented with market context from Pluang's Financials sector. For readers following Financials, here is Pluang's market snapshot as of Sep 29, 2026 00:41 WIB: out of 85 priced US Financials stocks, 11 rose and 73 fell. Notable movers include RIOT at USD 22.16 with a -3.67% change, KKR at USD 93.35 down 3.43%, and SOFI at USD 16.04 down 3.29%.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
1 hour ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
2 hours ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
3 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
3 hours ago
ICF awarded $70M to support SoCalREN's energy efficiency programs in Southern California.

ICF awarded $70M to support SoCalREN's energy efficiency programs in Southern California.

ICF has secured two new multiyear contracts worth about $70 million to implement energy efficiency programs for the Southern California Regional Energy Network (SoCalREN). These programs aim to reduce energy costs, enhance grid reliability, and suppo...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App